Uterine Fibroids Clinical Trial
Official title:
A Prospective Randomized Blinded Placebo Controlled Comparison of Multimodal Pre-emptive Analgesia on Long Term Outcome Following Uterine Artery Embolization
Uterine leiomyomata, also known as fibroids, are an extremely common benign lesion being
present in 30-50% of all women. Traditional surgical treatment of symptomatic fibroids has
been hysterectomy in post child bearing woman. However, over the last decade, the use of a
minimal invasive technique called uterine artery embolization has become increasingly
popular due to high patient satisfaction, cost effectiveness, and shorter recovery period.
The purpose of this randomized blinded placebo controlled study is to compare pre-emptive
analgesia vs non-preemptive analgesia for immediate postoperative pain control, long term
pain control, and improved quality of life in woman following uterine artery embolization
surgery. The study consists of four drug groups including a placebo group. The addition of
pregabalin and celecoxib together with epidural analgesia may improve pain management as
well as leading to a better post-procedure outcome in women following uterine artery
embolization.
Many investigators believe that the ischemia in the normal myometrium is the primary source
of pain immediately following surgery making postoperative pain management challenging.
Epidural fentanyl may offer an advantage when encountering visceral pain. In addition to
being an effective analgesic for chronic pain syndromes, the use of pregabalin provides
effective postoperative analgesia when it is administered pre-emptively before an operation.
Preemptive analgesia involves the introduction of an analgesic regimen before the onset of
noxious stimuli, with the goal of preventing sensitization of the nervous system to
subsequent stimuli that could amplify pain. In human trials, pregabalin has been
demonstrated to reduce pain, improve sleep, and mood disturbances in patients with post
herpetic neuralgia. The use of celecoxib in combination with pregabalin has shown to provide
more effective analgesia by providing antihyperalgesia. Therefore, the addition of
pregabalin and celecoxib together with epidural analgesia may improve pain management as
well as having an effect on long term sequelae.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01441635 -
Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids
|
Phase 2 | |
Completed |
NCT00958334 -
Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003
|
Phase 2 | |
Withdrawn |
NCT04567589 -
A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Healthcare Professionals in Canada
|
||
Recruiting |
NCT05078307 -
Evaluation of a Hysteroscopic Method With Vaporization in the Hysteroscopic Treatment of Submucosal Uterine Fibroids
|
N/A | |
Recruiting |
NCT02283502 -
Clinical Test of the MRgHIFU System on Uterine Fibroids
|
Phase 1 | |
Completed |
NCT01739621 -
Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200
|
Phase 2 | |
Completed |
NCT01631903 -
Extension of Study ZPV-200
|
Phase 2 | |
Withdrawn |
NCT00768742 -
Safety and Effectiveness Study of RF Ablation of Uterine Fibroids to Reduce Menstrual Bleeding: the Fibroid Ablation Study
|
N/A | |
Completed |
NCT00152256 -
A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine Fibroids
|
Phase 3 | |
Not yet recruiting |
NCT03586947 -
Association Between Vitamin D and the Risk of Uterine Fibroids
|
N/A | |
Completed |
NCT02925494 -
An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
|
Phase 3 | |
Not yet recruiting |
NCT06055114 -
Study on Vaginal Microecology and Cervical Local Immune Function in Patients With Uterine Fibroids of Childbearing Age
|
||
Terminated |
NCT05026502 -
A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of Bleeding in Adult Participants With Heavy Menstrual Bleeding Due to Uterine Fibroids Taking Oral Oriahnn Capsules
|
||
Withdrawn |
NCT04567095 -
A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Patients in Canada
|
||
Withdrawn |
NCT03699176 -
Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids
|
Phase 3 | |
Not yet recruiting |
NCT02884960 -
Safety and Efficacy of Embozene Microspheres for Uterine Fibroid Embolization
|
N/A | |
Completed |
NCT02472184 -
Optimal Order of Concurrent Office Hysteroscopy and Endometrial Biopsy
|
N/A | |
Completed |
NCT01452659 -
Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids
|
Phase 2 | |
Completed |
NCT01229826 -
Magnetic Resonance Elastography (MRE) of Uterine Fibroids
|
N/A | |
Terminated |
NCT00737282 -
Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids
|
Phase 3 |